australian biotech

Latest news and analysis on australian biotech

Equities

When the market’s hot, go where it’s not: Biotech’s position of opportunity for FY26

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market.
OPT
+3
Charlie Williams
HB Biotechnology
Equities

Syntara!

Extended interview with CEO Gary Phillips
SNT
Michael Frazis
Frazis Capital
Equities

There's more to Australian biotech than just CSL: the opportunities to watch

Despite the uncertainty, there's plenty of progress in the Australian biotech space.
CVB
DXB
+5
Hashan De Silva
KP Rx
Equities

What it will take to create the next CSL or Telix Pharmaceuticals

The Aussie biotech space is small but mighty – what will it take to see it surge?
Sara Allen
Livewire Markets
4